2011肥厚型心肌病（HCM）诊治指南课件_2.pptVIP

2011 ACCF/AHA肥厚型心肌病（HCM）诊治指南 美国胸外科协会、美国超声心动力图学会、美国核心脏病学学会、美国心力衰竭学会、心脏节律学会、心血管造影和介入学会、胸腔外科学会合作开发 © American College of Cardiology Foundation and American Heart Association, Inc. 广西柳州市人民医院 心内科胡世红教授译 引证 这套幻灯片改编自2011 ACCF/AHA肥厚型心肌病诊治指南 (Journal of the American College of Cardiology). 2011-11-08发表，在下述网站可找到: /cgi/content/full/j.jacc.2011.06.011 指南全文在下述网站也可找到: ACC () and AHA () Slide Set Editors Bernard J. Gersh, MB, ChB, DPhil, FACC, FAHA, Co-Chair Barry J. Maron, MD, FACC, Co-Chair The Diagnosis and Treatment of HCM Guideline Writing Committee Members Bernard J. Gersh, MB, ChB, DPhil, FACC, FAHA, Co-Chair Barry J. Maron, MD, FACC, Co-Chair Special Thanks To Steve R. Ommen, MD, FACC, FAHA Harry Rakowski, MD, FACC, FASE Christine E. Seidman, MD, FAHA Jeffrey A. Towbin, MD, FACC, FAHA James E. Udelson, MD, FACC, FASNC Clyde W. Yancey, MD, FACC, FAHA Robert O. Bonow, MD, MACC, FAHA Joseph A. Dearani, MD, FACC Michael A. Fifer, MD, FACC, FAHA Mark S. Link, MD, FACC, FHRS Srihari S. Naidu, MD, FACC, FSCAI Rick A. Nishimura, MD, FACC, FASE 推荐类别和证据水平 A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.   *Data available from clinical trials or registries about the usefulness/ efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use. †For comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated. 诊断 Guideline for HCM 基因检测 策略/家族筛查 Diagnosis 作为HCM患者评估的一部分推荐进行家族性遗传评估和遗传咨询。 进行了基因检测的患者还应当由心血管病遗传知识渊博的专家进行遗传咨询，以便能与患者一起